Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.
Memo Therapeutics AG, based in Basel, Switzerland, specializes in innovative antibody discovery and immune repertoire analysis. The company utilizes its proprietary MemoMAB platform, which generates a recombinant in vitro copy of an individual's B cell or antibody repertoire, creating extensive libraries that represent unique immune responses. These libraries are expected to contain a vast array of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics applies this technology in its own antibody lead discovery programs and partners with other entities to enhance research and development in the fields of viral infections and cancer. Through its advancements, Memo Therapeutics aims to significantly improve therapeutic options for patients.
Neurona Therapeutics Inc. is a biotechnology company based in South San Francisco, California, that specializes in developing cell-based therapies for neurological disorders. Founded by neuroscientists and stem cell pioneers at The University of California, San Francisco, the company focuses on creating therapeutic compositions of specific types of neurons for targeted delivery into the injured nervous system. Drawing on nearly two decades of research, Neurona seeks to harness particular subpopulations of neurons capable of integrating and repairing dysregulated neural circuits. With a dedicated team of scientists and advisors, the company aims to accelerate the development of breakthrough treatments for patients suffering from significant unmet medical needs in the realm of chronic neurological diseases.
Kynexis is focused on developing a precision medicine aimed at treating cognitive impairment associated with schizophrenia (CIAS). The company's innovative research utilizes a human biology-based approach to identify causal biomarkers that inform its mechanism of action during clinical development. Additionally, Kynexis employs a human genetics strategy to pinpoint specific sub-populations of patients who are likely to respond positively to the treatment. Through these methods, Kynexis seeks to enhance brain function in individuals affected by schizophrenia, addressing a critical need in mental health care.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.
NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
CytoKi Pharma ApS is a discovery-stage biotechnology company based in Værløse, Denmark, founded in 2019. The company focuses on developing innovative treatments for diseases with significant unmet medical needs, particularly those resulting from epithelial injury. CytoKi Pharma is currently in the pre-clinical stage and is advancing its lead program, which involves an engineered long-acting IL-22 protein licensed from a major pharmaceutical entity. IL-22 is a crucial cytokine that plays a vital role in the immune system's response to tissue injury, acting as a signal for survival and recovery. By harnessing the therapeutic potential of this modified IL-22 protein, CytoKi Pharma aims to address the challenges posed by organ injuries and improve patient outcomes in affected populations.
ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the natural functioning of the brain. The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need.
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.
Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.
Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.
Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.
Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.
OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.
Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.
DermaLumics is a global medical device company that specializes in advanced optical coherence tomography (OCT) technology, aimed at enhancing skincare through innovative imaging solutions. The company has developed a handheld diagnostic device designed to assist dermatologists in the minimally invasive diagnosis of skin cancer. This technology not only aids in the early detection of skin-related issues but also enables patients to better maintain the health of their skin, hair, and nails. By focusing on these advanced imaging capabilities, DermaLumics seeks to transform the way skincare is approached and managed in the medical field.
SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
Kala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, that specializes in developing therapies for diseases affecting mucosal tissues using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology. This innovative approach enhances drug distribution and pharmacokinetics by delivering biocompatible, drug-loaded particles that uniformly coat mucosal surfaces. The company's lead product candidate, KPI-121 0.25%, has successfully completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS, another product, has also completed two Phase III trials for treating inflammation and pain following ocular surgery. Kala is advancing its pipeline, including KPI-285, a receptor tyrosine kinase inhibitor for retinal diseases, which is currently in preclinical studies. The company aims to address significant clinical needs while exploring research collaborations to enhance its product offerings.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Inbiomotion is dedicated to the development and commercialization of a biomarker that predicts metastasis, with the aim of enhancing the quality of life for breast cancer patients through personalized adjuvant treatment. Established in 2010 as a spin-off from IRB Barcelona and ICREA, the company has created a diagnostic assay based on a highly selective single-gene biomarker. This biomarker has shown promise in identifying early-stage breast cancer patients who are likely to benefit from bisphosphonate adjuvant treatment, potentially improving their overall survival and reducing the risk of invasive disease. Additionally, the biomarker can predict the likelihood of metastases relapse from primary tumors at an early stage, positioning Inbiomotion to advance clinical practices in personalized medicine for breast cancer care.
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.
Sabirmedical is a biomedical research and development company located in the Bioincubator PCB-Santander space at Barcelona Science Park with a clear focus in the development of novel technologies for diagnostics, home and patient care in the field of cardiovascular monitoring.
Cardoz AB manufactures anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The company was founded in 2006 and is based in Stockholm, Sweden.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.